Filing Flows › Comparisons › LCTX vs DYAI
Lineage Cell Therapeutics vs Dyadic International: LCTX and DYAI compared
Lineage Cell Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $961K for Dyadic International (Q2 2026). Dyadic International is growing faster (-0.6% against -61% a year earlier). Dyadic International is more profitable, with an operating margin of -213.7% against -834.7%.
Where the money goes: LCTX and DYAI
Lineage Cell Therapeutics (LCTX) · Q2 2026
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Dyadic International (DYAI) · Q2 2026
Dyadic International, Q2 2026: revenue $961K (-0.6% year over year), operating margin -213.7%, net loss $2.1M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
| Lineage Cell Therapeutics (LCTX) | Dyadic International (DYAI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.1M | $961K |
| Revenue growth, Y/Y | -61% | -0.6% |
| Operating margin | -834.7% | -213.7% |
| Net earnings | $1.5M | −$2.1M |
| Net margin | 144.4% | -221.0% |
| Operating cash flow | −$7.2M | −$1.8M |
Where the revenue comes from
Lineage Cell Therapeutics
- Collaboration Revenues: $943K (88%)
- Royalties License and Other Revenues: $126K (12%)
Dyadic International
- Grant: $837K (87%)
- Research and Development: $124K (13%)
Questions
Which is bigger, Lineage Cell Therapeutics or Dyadic International?
Lineage Cell Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $961K for Dyadic International (Q2 2026).
Is Lineage Cell Therapeutics or Dyadic International growing faster?
Dyadic International is growing faster (-0.6% against -61% a year earlier).
Which is more profitable, Lineage Cell Therapeutics or Dyadic International?
Dyadic International is more profitable, with an operating margin of -213.7% against -834.7%.
More: Lineage Cell Therapeutics earnings · how Lineage Cell Therapeutics makes money · Dyadic International earnings · how Dyadic International makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.